2019 sales: $7.12 billion
Projected 2026 sales: $1.7 billion
Projected CAGR: -19%
Used for: ovarian cancer; epithelial ovarian, fallopian tube, or primary peritoneal cancer; cervical cancer; kidney cancer; glioblastoma; non-small cell lung cancer; colorectal cancer
Roche is in the midst of an biosimilar onslaught to its trio of oncology blockbusters, including its biggest-selling cancer drug, Avastin. With copycats hitting the U.S. in 2019, Avastin's days in the highest ranks of pharma's bestsellers is now almost certainly at a close.
Avastin picked up $7.12 billion in sales in 2019 but faces a steep decline in the coming years. Evaluate tabulated the oncology med's 2026 sales at just $1.7 billion—still a blockbuster but not much to look at anymore.
The back half of 2019 was marked by the launch of the first Avastin biosim in the U.S.
Amgen and Allergan were the only drugmakers that chose not to settle with Roche for a delayed launch date. The group of drugmakers that chose to hold off on a biosimilar launch included Mylan, Pfizer, Samsung Bioepis and the Teva Pharmaceutical-Celltrion team.
In fact, the launch of two biosims (so far) hasn't deterred Roche from working to fend off more contenders. In June, the Swiss drugmaker's Genentech unit sued Samsung Bioepis for patent infringement, aiming to keep the Samsung Biologics-Biogen joint venture's version off the market.